Over the past two days, Poietis Biosystems had the great pleasure of welcoming the 3d.FAB technological platform team, along with their director Christophe Marquette, to our facilities for two days of rich exchanges and technical collaboration.
This visit provided an excellent opportunity to thoroughly evaluate the capabilities of our Next-Generation Bioprinting (NGB) platform and confront it with the latest innovations in tissue engineering.
1) Evaluating PickCell Technology for Organoid Printing
We successfully assessed the integration and application of PickCell technology. These precision bioprinting trials are a core part of the LIFT Industrial Chair (Large-scale Innovative Fabrication of in vitro engineered Tissues).
Supported by the ANR, this ambitious project aims to drive a French revolution in the in vitro bio-fabrication of human tissues.
Source: Lancement de la Chaire Industrielle LIFT (ANR)
2) Validating NGB Platform Compatibility with Fugu Systems
The team also successfully validated the compatibility of our NGB platform with the “Fugu” confinement systems developed by 3d.FAB.
- Sterile conditions: These specialized dome-shaped bioreactors are designed to ensure an optimal culture environment during the bioprinting process.
- Scaling up: Validating this compatibility represents a crucial technological step for scaling up the bioproduction of complex tissues securely.
3) A shared vision for regenerative medicine
These productive days of experimentation strengthen the synergies between Poietis Biosystems and leading players in French research like 3d.FAB. Together, we are taking another step toward the standardization and industrialization of bioprinted tissues for regenerative medicine and pharmaceutical research.
READY TO ACCELERATE YOUR 3D TISSUE BIOPRODUCTION?
Let’s discuss about NGB-RTM
CONTACT US FOR A DEMO – Or – Follow us on Linkedin
